ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia

    - Collaboration leads to major deals in Asia
    - Annual revenue to reach $60 M for ProMetic in product sales and
    - Sartorius Stedim Biotech expects significant demand for its products
      and services

    AUBAGNE, France, GOETTINGEN, Germany and MONTREAL, Canada, March 18 /CNW
Telbec/ - Sartorius Stedim Biotech and ProMetic Life Sciences Inc.
("ProMetic") (TSX:PLI) announced today the second successful technology
transfer deal resulting from their collaboration entered into in 2006. The
collaboration positions Sartorius Stedim Biotech as the preferred supplier and
technology provider of filtration equipment and consumables to plasma
fractionators that have in-licensed ProMetic's proprietary manufacturing
    ProMetic recently announced that they have signed a strategic alliance
and license agreement with the Wuhan Institute of Biological Products
("WIBP"). Under the terms of this agreement, WIBP gains exclusive access to
ProMetic's yield improving plasma protein process for the Chinese market. In
addition ProMetic has announced agreements with the Taiwanese biotechnology
company Blue-Blood Biotech Corporation ("Blue Blood") for the development and
commercialization of human plasma-derived specialty immunoglobulin
preparations for the treatment of several infectious diseases including
Cytomegalovirus and Enterovirus. Under this agreement, ProMetic would also
retain the rights to the hyperimmune products for the North American market.
    "These agreements and our relationship with Sartorius Stedim Biotech
contribute to our short term revenue growth and to making our Protein
Technologies business EBITDA positive in 2008 and generating an EBITDA of
$15 to $20 Million in 2009," stated Mr. Pierre Laurin, President and Chief
Executive Officer of ProMetic. "Collectively, these agreements have firmly
established ProMetic's technology in Asia and provide an opportunity to
generate an estimated $60 Million in annual product sales and royalties for
ProMetic, with the first plasma-derived products expected to be commercialized
in 2011 in Asia and in North America."
    As filtration and fluid management technologies are an integral aspect to
the purification of biological products, Sartorius expects significant sales
from this collaboration. Due to its comprehensive portfolio of innovative
technologies and services Sartorius is able to provide turn key solutions for
the downstream processes of the licensees.
    Dr. Uwe Gottschalk, Vice President of Purification Technologies at
Sartorius Stedim Biotech, stated "This association allows us to combine
ProMetic's proprietary technology and Sartorius' integrated technology
portfolio to bypass current bioseparation limitations. In doing so, we
generate increased yields for plasma-derived proteins and therefore enhance
the profitability of the existing processes at our customers."

    About ProMetic Life Sciences Inc.

    ProMetic Life Sciences Inc. ( is a biopharmaceutical
company specialized in the research, development, manufacture and marketing of
a variety of commercial applications derived from its proprietary Mimetic
Ligand(TM) technology. This technology is used in large-scale purification of
biologics and the elimination of pathogens. ProMetic is also active in
therapeutic drug development with the mission to bring to market effective,
innovative, lower cost, less toxic products for the treatment of hematology
and cancer. Its drug discovery platform is focused on replacing complex,
expensive proteins with synthetic "drug-like" protein mimetics. Headquartered
in Montréal (Canada), ProMetic has R&D facilities in the UK, the USA and
Canada, manufacturing facilities in the UK and business development activities
in the USA, Europe, Asia and in the Middle-East.

    Forward Looking Statements

    This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks
affect our business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited to,
ProMetic's ability to develop, manufacture, and successfully commercialize
value-added pharmaceutical products, the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of ProMetic to take advantage of business opportunities
in the pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or results to
materially differ from our current expectations on page 21 of ProMetic's
Annual Information Form for the year ended December 31, 2006, under the
heading "Risk Factors". As a result, we cannot guarantee that any
forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a
result of future events or for any other reason, unless required by applicable
securities laws and regulations.

    About Sartorius Stedim Biotech

    Sartorius Stedim Biotech ( is a leading provider
of cutting-edge equipment and services for the development, quality assurance
and production processes of the biopharmaceutical industry. Its integrated
solutions covering fermentation, filtration, purification, fluid management
and lab technologies are supporting the biopharmaceutical industry around the
world to develop and produce drugs safely, timely and economically. For next
generation processes, Sartorius Stedim Biotech focuses on single-use
technologies and added-value services to meet the rapidly changing technology
requirements of the industry it serves. Strongly rooted in the scientific
community and closely allied with customers and technology partners, the
company is dedicated to its philosophy of "Turning science into solutions."
    Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on
the Eurolist of Euronext Paris. With its own manufacturing and sales companies
in Europe, North America and Asia, Sartorius Stedim Biotech enjoys a worldwide
presence. Its key manufacturing and R&D location is in Germany. The company
employs over 2,300 people and earned in 2007 pro forma sales revenue of
375.9 million euros.

For further information:

For further information: ProMetic Inquiries: Pierre Laurin, President
and CEO, ProMetic Life Sciences Inc., (514) 341-2115,; 
Anne Leduc, Manager, Investor Relations & Communications, ProMetic Life
Sciences Inc., (514) 341-2115,; Dominic Sicotte, Echoes
Financial Network Inc., (514) 842-9551,; Investor
Relations: Bruce Voss, Lippert/Heilshorn & Associates, (310) 691-7100,; Kim Golodetz, Lippert/Heilshorn & Associates, (212) 838-3777,;  Media Relations: Jules Abraham, Lippert/Heilshorn &
Associates, (212) 838-3777,; Sartorius Inquiries: Dominic
Grone, Group Corporate Communications, Sartorius Corporate Administration
GmbH, +49.551.308.3324,; Daniela Winzker-Demes,
Business Development, Sartorius Stedim Biotech GmbH, +49.551.308.3879,

Organization Profile


More on this organization


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890